Literature DB >> 29063734

Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer.

Giorgio Gandaglia1,2, Emanuele Zaffuto1,2,3, Nicola Fossati1,2, Marco Bandini1,2, Nazareno Suardi1,2, Elio Mazzone1,2, Paolo Dell'Oglio1,2, Armando Stabile1,2, Massimo Freschi3, Francesco Montorsi1,2, Alberto Briganti1,2.   

Abstract

OBJECTIVES: To assess if the preoperative lymph node invasion (LNI) risk could be used to tailor the extent of pelvic lymph node dissection (PLND) according to individual profile in patients with prostate cancer (PCa) undergoing radical prostatectomy (RP), and to identify those who would benefit from the removal of the common iliac and pre-sacral nodes. PATIENTS AND METHODS: A total of 471 patients with high-risk PCa treated with RP and a super-extended PLND that included the removal of the pre-sacral and common iliac nodes between 2006 and 2016 were identified. The risk of LNI was calculated according to the Briganti nomogram. Multivariable logistic regression analyses assessed the association between LNI risk and involvement of the common iliac and pre-sacral regions. The risk of positive common iliac and pre-sacral nodes was plotted over the LNI risk using the LOWESS-smoothed fit curve.
RESULTS: The median preoperative LNI risk was 25.5%. The median number of nodes removed was 23, and 171 (36.3%) patients had LNI. Overall, 61 (13.0%) and 28 patients (5.9%), respectively, had positive common iliac and pre-sacral nodes alone or in combination with other sites. The LNI risk was associated with the involvement of the common iliac and pre-sacral regions (all P < 0.001). The proportion of patients with positive common iliac and pre-sacral nodes progressively increased according to the LNI risk. The adoption of a 30% threshold would result in avoiding the removal of the common iliac and pre-sacral nodes in >60% cases, with a risk of missing LNI in these regions of <5%.
CONCLUSIONS: Fewer than 5% of patients with an LNI risk of <30% harbour positive common iliac and pre-sacral nodes. A super-extended PLND that includes the dissection of these regions should be considered exclusively in patients with an LNI risk ≥30%.
© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; lymph node invasion; pelvic lymph node dissection; radical prostatectomy

Mesh:

Year:  2017        PMID: 29063734     DOI: 10.1111/bju.14066

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  4 in total

Review 1.  Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy-Do We Know the Proper Way of Management?

Authors:  Bartosz Małkiewicz; Miłosz Knura; Małgorzata Łątkowska; Maximilian Kobylański; Krystian Nagi; Dawid Janczak; Joanna Chorbińska; Wojciech Krajewski; Jakub Karwacki; Tomasz Szydełko
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

2.  Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer.

Authors:  Heikki Seikkula; Pieter Janssen; Manuela Tutolo; Lorenzo Tosco; Antonino Battaglia; Lisa Moris; Thomas Van den Broeck; Maarten Albersen; Gert De Meerleer; Hendrik Van Poppel; Wouter Everaerts; Steven Joniau
Journal:  Front Oncol       Date:  2017-11-22       Impact factor: 6.244

3.  Difference in Frequency and Distribution of Nodal Metastases Between Intermediate and High Risk Prostate Cancer Patients: Results of a Superextended Pelvic Lymph Node Dissection.

Authors:  Marco Roscigno; Maria Nicolai; Giovanni La Croce; Federico Pellucchi; Manuela Scarcello; Antonino Saccà; Diego Angiolilli; Daniela Chinaglia; Luigi F Da Pozzo
Journal:  Front Surg       Date:  2018-09-07

Review 4.  Developing a personalized template for lymph node dissection during radical prostatectomy.

Authors:  Ram A Pathak; Ashok K Hemal
Journal:  Transl Androl Urol       Date:  2018-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.